<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662632</url>
  </required_header>
  <id_info>
    <org_study_id>JPS-0301</org_study_id>
    <nct_id>NCT04662632</nct_id>
  </id_info>
  <brief_title>Abbreviated Protocol for Two-Stage Exchange</brief_title>
  <acronym>APEX</acronym>
  <official_title>A Randomized Controlled Trial of Alternating Irrigation of Vancomycin HCl and Tobramycin Sulfate in Patients Undergoing Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection of the Hip or Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osteal Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osteal Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Type: A multi-site, parallel group, randomized trial.&#xD;
&#xD;
      Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of&#xD;
      VT-X7. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint&#xD;
      of Overall Success at 90 days, consisting of a revision prosthesis implanted at Stage 2,&#xD;
      patient survival, absence of reoperation and absence of PJI. Secondary objectives are to&#xD;
      evaluate superiority at 365 days in a composite endpoint of Overall Success, and in separate&#xD;
      secondary endpoints for quality of life (QoL) and patient survival. The exploratory objective&#xD;
      is to compare Experimental and Control Arms in exploratory endpoints.&#xD;
&#xD;
      Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients will be blinded to their randomization arm assignment until the completion of Stage 1 surgery.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of Overall Success at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Composite endpoint of Overall Success at 90 days consisting of:&#xD;
Stage 2 revision prosthesis implanted;&#xD;
Absence of PJI* post-Stage 2;&#xD;
Absence of reoperation*** of the affected joint pre- or post- Stage 2; and&#xD;
Absence of mortality.&#xD;
If clinical evidence of infection is present post-Stage 2 surgery, use ICMMI 2018 for definitive PJI confirmation.&#xD;
Reoperation includes only procedures to irrigate, debride, and remove or replace the Stage 1 spacer or any Stage 2 implant component.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of Overall Success at 180 days</measure>
    <time_frame>180 days</time_frame>
    <description>Composite endpoint of Overall Success at 180 days consisting of:&#xD;
Stage 2 revision prosthesis implanted;&#xD;
Absence of PJI* post-Stage 2;&#xD;
Absence of continued antibiotic therapy for treatment or prophylaxis of PJI **;&#xD;
Absence of reoperation*** of the affected joint pre- and post-Stage 2; and&#xD;
Absence of mortality.&#xD;
If clinical evidence of infection is present post-Stage 2 surgery, use ICMMI 2018 for definitive PJI confirmation.&#xD;
Continued antibiotic therapy includes antibiotic therapy at 180 days or beyond 12 weeks post-Stage 2 surgery, excluding antibiotics for documented pre-procedural prophylaxis or infection other than PJI.&#xD;
Reoperation includes only procedures to irrigate, debride, remove or replace the Stage 1 spacer or any Stage 2 implant component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of Overall Success at 365 days consisting of:</measure>
    <time_frame>365 days</time_frame>
    <description>Composite endpoint of Overall Success at 365 days consisting of:&#xD;
Stage 2 revision prosthesis implanted;&#xD;
Absence of PJI* post-Stage 2;&#xD;
Absence of continued antibiotic therapy for treatment or prophylaxis of PJI **;&#xD;
Absence of reoperation*** of the affected joint pre- and post-Stage 2; and&#xD;
Absence of mortality.&#xD;
If clinical evidence of infection is present post-Stage 2 surgery, use ICMMI 2018 for definitive PJI confirmation.&#xD;
Continued antibiotic therapy includes antibiotic therapy at 365 days or beyond 12 weeks post-Stage 2 surgery, excluding antibiotics for documented pre-procedural prophylaxis or infection other than PJI.&#xD;
Reoperation includes only procedures to irrigate, debride, remove or replace the Stage 1 spacer or any Stage 2 implant component.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per SOC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SOC for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>VT-X7 Treatment System</intervention_name>
    <description>Seven-day local antibiotic irrigation (alternating tobramycin sulfate and vancomycin HCl) via the VT-X7 Knee or Hip Spacer with alternating NPWT.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per SOC. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Two-stage exchange arthroplasty</intervention_name>
    <description>Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for two-stage exchange arthroplasty due to hip or knee PJI&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  22 to 84 years of age (inclusive)&#xD;
&#xD;
          -  Medical clearance for surgery&#xD;
&#xD;
          -  Preoperative diagnosis of PJI of the hip or knee per the International Consensus&#xD;
             Meeting of Musculoskeletal Infection (ICMMI) 2018 definition of Periprosthetic Hip and&#xD;
             Knee Infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with 2 or more prior one-stage or two-stage exchange arthroplasties of the&#xD;
             infected joint;&#xD;
&#xD;
          -  Patients with acute PJI, defined as total joint arthroplasty surgery within 4 weeks&#xD;
             prior to enrollment (Stage 1) in this study;&#xD;
&#xD;
          -  Patients with bacteremia or positive bacterial blood culture in the last 6 months;&#xD;
&#xD;
          -  Patients with concurrent PJI of more than one joint;&#xD;
&#xD;
          -  Patients with ongoing active infection of an intravenous (IV) site;&#xD;
&#xD;
          -  Patients who require long-term anticoagulation or antiplatelet therapy, and for whom&#xD;
             bridging or withholding therapy is not recommended based on the individual's clinical&#xD;
             condition;&#xD;
&#xD;
          -  Patients with advanced renal insufficiency (chronic kidney disease (CKD) Stage 4 or&#xD;
             greater or glomerular filtration rate (GFR) &lt;30 mL/min);&#xD;
&#xD;
          -  Patients on chemotherapy for malignant disease;&#xD;
&#xD;
          -  Patients on systemic glucocorticoid therapy (prednisone &gt;5 mg/day or equivalent);&#xD;
&#xD;
          -  Patients with immunodeficiency (e.g., splenectomy, sickle cell anemia, Stage 3 human&#xD;
             immunodeficiency virus (HIV) infection, primary humoral immunodeficiency, or bone&#xD;
             marrow or other transplantation);&#xD;
&#xD;
          -  Patients who have an allergy to vancomycin HCl or tobramycin sulfate (Note: prior&#xD;
             history of red man syndrome is not considered an allergy);&#xD;
&#xD;
          -  Patients who have an allergy to titanium, titanium alloys, polymethylmethacrylate or&#xD;
             polyurethane.&#xD;
&#xD;
          -  Patients who are pregnant or planning to become pregnant in the next 12 months;&#xD;
&#xD;
          -  Patients in whom NPWT is contraindicated;&#xD;
&#xD;
          -  Patients with a PJI pathogen that is not considered susceptible to vancomycin HCl or&#xD;
             tobramycin sulfate, per the Principal Investigator's (PI's) opinion, including fungal&#xD;
             infection;&#xD;
&#xD;
          -  Patients who have a &quot;megaprosthesis&quot; addressing a large skeletal defect in the&#xD;
             infected joint;&#xD;
&#xD;
          -  Patients who have a planned surgical procedure within 6 months of enrollment that can&#xD;
             impact the conduct of the study;&#xD;
&#xD;
          -  Patients who are breastfeeding at the screening visit;&#xD;
&#xD;
          -  Patients who are incarcerated or are facing impending incarceration;&#xD;
&#xD;
          -  Patients who are currently abusing drugs or alcohol or have been in treatment for&#xD;
             substance abuse within the past year;&#xD;
&#xD;
          -  Patients with any medical condition, including schizophrenia or another psychiatric&#xD;
             disorder with hallucinations and/or delusions, that would interfere with the&#xD;
             interpretation of the study results, the conduct of the study, or patient&#xD;
             participation would not be in the best interest of the patient in the opinion of the&#xD;
             Study Site PI;&#xD;
&#xD;
          -  Patients who have participated in another clinical study of another investigational&#xD;
             drug or investigational device within the past 30 days;&#xD;
&#xD;
          -  Patients who are judged by the PI to be unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Branko Kopjar, M.D., PhD</last_name>
    <phone>206-607-6861</phone>
    <email>jps301@nor-consult.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Pflaster</last_name>
    <phone>802-999-5925</phone>
    <email>dpflaster@ostealtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Ghanem</last_name>
      <email>eghanem@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rhonda Corvalan</last_name>
      <email>rcorvalan@uabmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis Kwong</last_name>
      <email>LKwong@dhs.lacounty.gov</email>
    </contact>
    <contact_backup>
      <last_name>Elaine Santana</last_name>
      <email>esantana@lundquist.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katharine Harper</last_name>
      <email>Katharine.Harper@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Priscilla Adler</last_name>
      <email>Priscilla.Adler@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hari Parvataneni</last_name>
      <email>parvahk@ortho.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Leitz</last_name>
      <email>leitzrs@ortho.ufl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Higuera-Rueda</last_name>
      <email>HIGUERC@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Duncan</last_name>
      <email>stdunc2@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cale Jacobs</last_name>
      <email>cale.jacobs@uky.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Covenant Medical Center</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian De Beaubien</last_name>
      <email>bdebeaubien@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jean Reif</last_name>
      <email>Jean.Reif@chs-mi.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ran Schwarzkopf</last_name>
      <email>Ran.Schwarzkopf@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Waren</last_name>
      <email>Daniel.Waren@nyulangone.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Cooper</last_name>
      <phone>917-861-8984</phone>
      <email>jcooper02@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jacquelynne Lenahan</last_name>
      <phone>917-583-2885</phone>
      <email>jl5092@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina Research Institute, Inc</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Springer</last_name>
      <email>Bryan.Springer@orthocarolina.com</email>
    </contact>
    <contact_backup>
      <last_name>Taylor Rowe</last_name>
      <email>Taylor.Rowe@orthocarolina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Piuzzi</last_name>
      <email>piuzzin@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Alison Klika</last_name>
      <phone>917-583-2885</phone>
      <email>KLIKAA@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Glassman</last_name>
      <email>Andrew.Glassman@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Sheridan</last_name>
      <phone>614-293-9013</phone>
      <email>elizabeth.sheridan@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Integris Southwest Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Reddick</last_name>
      <email>osu2doc@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Suan Jones</last_name>
      <email>Susan.Jones@integrisok.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul M Courtney</last_name>
      <email>Paul.Courtney@rothmanortho.com</email>
    </contact>
    <contact_backup>
      <last_name>Thema Nicholson</last_name>
      <email>thema.nicholson@rothmanortho.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken Urish</last_name>
      <email>kruthm@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tina Vita</last_name>
      <email>vitatm@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanna Loughmiller</last_name>
      <email>Shanna.Loughmiller@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenna Blackburn</last_name>
      <phone>859-533-5996</phone>
      <email>brenna.blackburn@utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip</keyword>
  <keyword>Knee</keyword>
  <keyword>Biofilm</keyword>
  <keyword>Minimum-biofilm-eradication-concentration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

